LATEST

• BUSINESS Takeda CEO Pulls in 2.3 Billion Yen in FY2025
  June 18, 2026

• BUSINESS Elevidys Needs More Safety Data to Support Full Approval: Expert
  June 18, 2026

• BUSINESS Sawai’s Revlimid Generic Gains Additional Lymphoma Indications
  June 18, 2026

• REGULATORY Nippon Ishin Calls for Pharma to Be Designated Strategic Industry
  June 18, 2026

• BUSINESS Efient AGs Widen Labels to Close Indication Gap
  June 18, 2026

• BUSINESS AZ, Kyoto Ink Pact to Promote NCD Prevention, Early Detection
  June 18, 2026

• REGULATORY New Chuikyo Payer Rep Wary of Blanket Inflation Adjustment for Reimbursement
  June 17, 2026

• REGULATORY CEA Review Group Discusses Evidence for Additional Usefulness
  June 17, 2026

• REGULATORY Japan Sets 6-Billion-Yen Donation Target for Drug Discovery Fund
  June 17, 2026

• BUSINESS Takeda Reports Additional Benefits for Narcolepsy Drug Oveporexton
  June 17, 2026

• REGULATORY Drug Makers Back Patent Protection for AI-Generated Inventions: JPO
  June 17, 2026

• REGULATORY LDP Panel Calls for Action on Women’s Health Issues in Policy Proposals
  June 17, 2026

• BUSINESS Adstiladrin Expected to Ease Patient Burden in Bladder Cancer: Experts
  June 17, 2026

• REGULATORY PMDA Flags PPI/P-CAB Drugs, Checkpoint Inhibitors, and Others in Risk Review
  June 17, 2026

• REGULATORY Nippon Ishin Calls for Integrated Use of Medical Data
  June 17, 2026

• BUSINESS Astellas CEO’s Pay Rises to 733 Million Yen in FY2025: Securities Report
  June 17, 2026

• REGULATORY Panel Questions Timing of Tavneos Blue Letter Action
  June 17, 2026

• BUSINESS Torii Starts PIII Trial of Cantharidin for Common Warts
  June 17, 2026

• REGULATORY Minister Signals Chuikyo Review of Innovation Incentives after Roadmap
  June 17, 2026

• REGULATORY Limas, Ezharmia Among Drugs Subject to Label Revisions
  June 17, 2026

ページ

• « 先頭
• ‹ Prev
• …
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• …
• Next ›
• 最終 »